secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2026-09-28T11:15:10+00:00
Accession:  0001437749-26-031281
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Eton Pharmaceuticals launches IMPAVIDO (miltefosine) in U.S., its 11th commercial rare disease product
--------------------------------------------------------------------------------

- U.S. commercial launch of IMPAVIDO (miltefosine) capsules; Eton holds exclusive U.S. commercialization rights for the antileishmanial therapy.
- IMPAVIDO is indicated for visceral, cutaneous and mucosal leishmaniasis in adults and adolescents at least 12 years old weighing 30 kg (66 lbs) or more.
- Eton Cares patient support includes $0 co-pay for eligible commercially insured patients and expanded patient assistance programs.
- Distribution via Anovo Specialty Pharmacy (e-prescribe Anovo #5 Memphis; referral fax 855-813-2039; line 877-469-4078); hospital consignment stocking and emergency access pathway.
- Eton now lists eleven commercial rare disease products, including KHINDIVI, INCRELEX, ALKINDI SPRINKLE and IMPAVIDO, plus five late-stage candidates (AMGLIDIA, ASN-001, ET-700, ET-800, ZENEO).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926031281/0001437749-26-031281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926031281/eton20260923c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-031281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer